greeksoup/ stock research
Stock research / United States / BMRN / FY2008

Biomarin Pharmaceutical (BMRN) FY2008 results: revenue $296 million

Biomarin Pharmaceutical Inc. (BMRN) reported revenue of $296 million for fiscal 2008, the year ended 31 December 2008. Net income was $31 million, and diluted earnings per share $0.29. The figures are the company's own, from the 10-K it filed with the SEC on 24 February 2011.

Revenue
$296 million
FY2008FY2008
Operating margin
13.4%
FY2008FY2008
Net income
$31 million
FY2008FY2008
Diluted EPS
$0.29
FY2008FY2008

this yearthe year beforeHover a bar for its figure.

The year in brief

Income statement (profit and loss)

$ millionFY2008Last 8 years
Revenue296
Cost of revenue52.5
Gross profit244
Gross margin82.3%
Research and development93.3
Selling, general and administrative107
Operating income39.8
Operating margin13.4%
Interest expense16.4
Pre-tax income33.4
Income tax2.6
Effective tax rate7.8%
Net income30.8
Net margin10.4%
Diluted EPS$0.29
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionFY2008Last 8 years
Operating cash flow-9.2
Capital expenditure56.4
Free cash flow-65.5
Free cash flow margin-22.1%
Cash from investing-19.1
Cash from financing22.8
Depreciation and amortisation17.6
Share-based compensation28.3
Diluted shares, weighted104m

Balance sheet

$ millionFY2008Last 8 years
Shareholders' equity277
Cash and equivalents223

10-K for the year ended 31 December 2008, filed 24 February 2011: the filing.